EuropaBios Executive Board and General Assembly of Members this week confirmed the appointment of Tjerk de Ruiter as Chairman of the association.
Symcel has announced the appointment of two new board members; Erik Walldén and Stefan Löfås. Both will play a key role in the companys corporate strategy to grow business in the research market and develop solutions for clinical diagnostics.
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Roches Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
How do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.
Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.
Silence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director.
Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.